To print: Select File and then Print from your browser's menu

Title: Combined Infliximab, Methotrexate More Effective Than Other Strategies in Early Rheumatoid Arthritis: Presented at EULAR

"Combined Infliximab, Methotrexate More Effective Than Other Strategies in Early Rheumatoid Arthritis: Presented at EULAR"

By Paula Moyer BERLIN, GERMANY -- June 15, 2004 -- Early treatment with a combination of infliximab (Remicade) and methotrexate is more effective than 3 other step-up and step-down treatment strategies for patients with rheumatoid arthritis, say researchers. Renée Allaart, MD, a consultant rheumatologist at the University of Leiden, in Leiden, the Netherlands, presented study findings here June 10th at the European Congress of Rheumatology. Dr. Allaart and colleagues undertook a multicenter, randomized, single-blind trial, and recruited 508 patients with newly diagnosed rheumatoid arthritis. The patients had experienced the signs and symptoms of the disease for less than 2 years, and none had previously taken disease-modifying antirheumatic drugs (DMARDs). The investigators randomized the patients to 4 groups. Group 1 received sequential monotherapy starting with methotrexate up to 25 mg per week, with the next treatment step sulphasalazin followed by leflunomide. Group 2 received step-up therapy starting with methotrexate, followed consecutively by sulphasalazin and hydroxychloroquine. Group 3 started with combined methotrexate, sulphasalazin, and prednisone, starting at 60 mg daily and tapered down to 7.5 mg daily. Group 4 received methotrexate at 7.5 mg per week for 2 weeks and then 15 mg per week, with injections of infliximab at doses of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks, with doses increased or reduced to 0 depending on the Disease Activity Score (DAS44). Adjustment in treatment for each strategy was dictated by 3 monthly calculations of DAS44, with the goal of achieving DAS44 2.4 or less. Blinded assessors obtained clinical outcomes, DAS44, and health assessment questionnaires. Two blinded physicians performed the Sharp/van der Heijde radiological scores (SHS). After 3 months, the average HAQ reduction was 0.4 and 0.3 in groups 1 and 2 respectively, with reductions of 0.8 and 0.7 in group 3 and 4 respectively. After 1 year of follow-up, the reduction in HAQ was 0.7 in groups 1 and 2, and 0.9 in groups 3 and 4 (P =.04). Median radiologic progressions after 1 year were 2.0 for group 1, 2.5 for group 2, 1.0 for group 3, and 0.5 for group 4 (P <.001). In group 1, 27% of patients did not show any radiological progression, compared to 29% in group 2, 37% in group 3, and 46% for group 4 (P =.007). The groups had similar rates of discontinuation and adverse events, said Dr. Allaart. [Presentation title: A Comparison of Clinical and Radiological Outcomes of Four Treatment Strategies for Early Rheumatoid Arthritis: Results of the BEST Trial. Abstract OP001]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.